TABLE 2.
Efficacy analysis of first‐line treatment for non‐squamous NSCLC patients.
| WT (n = 108) | Mutation (n = 53) | p‐values | |
|---|---|---|---|
| Total response | 0.830 | ||
| PR | 28 (25.93%) | 16 (30.19%) | |
| SD | 48 (44.44%) | 23 (43.39%) | |
| PD | 32 (29.63%) | 14 (26.42%) | |
| Pemetrexed ± platinum | 0.713 | ||
| PR | 18 (24.32%) | 7 (25.00%) | |
| SD | 32 (43.25%) | 11 (39.29%) | |
| PD | 24 (32.43%) | 10 (35.71%) | |
| Taxanes ± platinum | 0.351 | ||
| PR | 2 (12.50%) | 1 (20.00%) | |
| SD | 8 (50.00%) | 4 (80.00%) | |
| PD | 6 (37.50%) | 0 (0.00%) | |
| Chemotherapy + antiangiogenesis/immunotherapy | 0.790 | ||
| PR | 6 (46.15%) | 8 (40.00%) | |
| SD | 6 (46.15%) | 8 (40.00%) | |
| PD | 1 (7.70%) | 4 (20.00%) |
Note: p values were calculated through the chi‐square test or Fisher's exact test. p values < 0.05 were highlighted in bold.
Abbreviations: PD, progressive disease; PR, partial response; SD, stable disease.